MAP2K7 and ductal breast carcinoma in situ: It is plausible that an upstream gene mutation led to the differential activation of the AKT and MEK pathways in precancer state vs DCIS state and thus determines the efficacy of pathway targeting by small molecule inhibitors (LY294002 and PD0325901) in MCF10.AT1 and MCF10.DCIS cells16.